The US pharma industry is likely to be turned upside down as President Donald Trump, on September 25, said a 100-percent tariff on patented and branded foreign medicines will be enacted from Oct 1 unless firms already have started constructing U.S. manufacturing plants. The policy will impact key antibiotics, most notably Amoxicillin Trihydrate, with wide reliance on international supply chains.
The U.S. imported almost USD 252 billion worth of drugs in the past year, and tariffs would raise cost, tightening distributors' wallets and potentially causing treatment costs to rise for patients. Although major pharmaceutical companies have committed about USD 300 million of investments in domestic factories, it takes time to build such facilities, and most of these companies may still need to endure tariffs in the meantime.
Supply of Amoxicillin Trihydrate will likely constrict as inventories are siphoned off, and logistical issues added to the volatility within the market. October 1 is a date significant to the industry, and Amoxicillin Trihydrate will be one of the most affected drugs, symbolizing underlying tensions between health care affordability and trade protectionism within the U.S.
Selenis has effectively manufactured recycled PET chips using terephthalic acid sourced from Circ®, a textile-to-textile recycler based in Virginia. The chip production took place through a series of batches at Selenis' pilot plant in San-Giorgio, Italy. By utilizing inputs recovered from polycotton textile waste, Selenis has created high-quality PET chip, which has been further processed into DTY yarn. This yarn will play a crucial role in product development as Circ prepares for additional capsule launches. Selenis is leveraging the success of this initial collaboration phase and is committed to advancing towards an offtake partnership to support Circ's inaugural industrial facility.
Eduardo Santos, Head of Corporate Strategy at Selenis, remarked that the monomer synthesis showed a performance comparable to virgin terephthalic acid. He expressed optimism about the consistent quality of Circ's monomer output and anticipated future commercial success. Santos pointed out that the Circ partnership complements Selenis's existing mission and goals for a more sustainable textile industry. He further stated their anticipation of expanding upon this collaboration and providing support for Circ's forthcoming commercial production trials.
